Loading…

Loading grant details…

Completed HORIZON European Commission

AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant

€1.98M EUR

Funder European Commission
Recipient Organization Freiburger Medizintechnik Gmbh
Country Germany
Start Date Oct 01, 2022
End Date Sep 30, 2025
Duration 1,095 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190173644
Grant Description

Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseases and diabetes. There is currently no effective solution to treat the 16.3 mn infected dental implants (EU, 2019).

Freiburger Medizintechnik GmbH developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight periimplantitis.

AmbiJet® is the world’s first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ.

It disrupts the status-quo of medical technologies by preventing the reinfection of disinfected surfaces and shows maximum effectiveness without side nor adverse effects: pharmacological and chemical substances are no longer required. AmbiJet® reduces inflammation, saves dental implants and helps patients live a healthier life.

All Grantees

Freiburger Medizintechnik Gmbh

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant